Accelerate Diagnostics’ new blood culture kit demonstrated 94% or greater accuracy on positive blood cultures relative to matrix-assisted laser desorption/ionization (MALDI).
Accelerate Diagnostics, an in-vitro diagnostics company, recently announced new data on its Accelerate Arc Module and BC kit. Internal studies found that the kit demonstrated 94% or greater accuracy on positive blood cultures when compared to conventional matrix-assisted laser desorption/ionization (MALDI).
According to an April 25 company press release, one study seeded samples for 20 of the most prevalent organism species (totalling 100 isolates) that were incubated on a blood culture system (BD Bactec FX, BD). After flagging positive, the samples were then processed on the new ARC BC kit, and subsequently tested in triplicate on two MALDI systems (Bruker Biotyper, Bruker, and (Vitek MS, bioMérieux). The Arc-processed samples had an overall agreement of 100% with the Bruker Biotyper and 94% with the Vitek MS.
Another study, conducted with the Medical College of Wisconsin, processed 50 fresh positive blood cultures from the VersaTrek blood culture system on the Arc Module, which were subsequently tested in triplicate on the Bruker MALDI system. When comparing the results, it was found that the Arc enabled direct identification of microorganisms in 90% of blood cultures, with 100% agreement between the Arc and colony identification. Additionally, the Arc enabled identification in under 90 minutes, with less than five minutes of hands-on time.
“This data represents an important step in providing a workflow solution to help automate sample preparation for rapid and accurate microbial identification, saving hours of wait time and numerous manual steps to deliver results," said Shelley Campeau, co-author of the studies and director of Scientific and Clinical Affairs, Accelerate Diagnostics, in the press release.
Source: Accelerate Diagnostics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.